CMND Clearmind Medicine Inc.

Nasdaq clearmindmedicine.com


$ 1.01 $ 0.03 (2.82 %)    

Friday, 24-Oct-2025 15:36:28 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 1.01
$ 1.01
$ 0.96 x 500
$ 1.08 x 1
$ 0.98 - $ 1.02
$ 0.80 - $ 2.18
52,720
na
nm
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clearmind-medicine-enrolls-last-patient-for-first-cohort-of-phase-iiia-clinical-trial-evaluating-cmnd-100-proprietary-meai-based-oral-drug-candidate-for-aud-treatment

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

Core News & Articles

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusi...

Core News & Articles

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-medicine-enters-10m-convertible-note-agreement-with-institutional-investors-begins-with-555k-issuance-at-500k-purchase-price

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

Core News & Articles

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-medicine-receives-irb-approval-from-hadassah-medical-center-jerusalem-for-ongoing-phase-12a-clinical-trial-evaluating-cmnd-100-proprietary-meai-based-oral-drug-candidate-for-treatment-of-aud

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

Core News & Articles

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusi...

 clearmind-medicine-completes-site-initiation-at-tel-aviv-sourasky-medical-center-for-phase-iiia-clinical-trial-evaluating-cmnd-100-proprietary-oral-drug-candidate-for-aud

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-medicine-granted-us-patent-12350242-for-binge-behavior-regulators

https://ppubs.uspto.gov/api/pdf/downloadPdf/12350242?requestToken=eyJzdWIiOiJlMmEyMTIwZi01YWZmLTQ5NGMtYjFkYi1lZTVmMmQ3MzM4NDgiL...

 clearmind-medicine-receives-irb-approval-from-tasmc-in-tel-aviv-for-ongoing-phase-12a-clinical-trial-evaluating-cmnd-100-for-aud-treatment

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-doses-first-patient-in-phase-iiia-trial-of-psychedelic-based-cmnd-100-for-alcohol-use-disorder

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-medicine-enrolls-first-patient-in-phase-iiia-clinical-trial-for-cmnd-100-proprietary-meai-based-oral-drug-candidate-for-treatment-of-aud

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the...

 clearmind-medicine-engages-government-and-political-affairs-consulting-and-lobbying-firm-to-support-advancing-psychedelic-based-treatments

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-adds-tel-aviv-hospital-to-psychedelic-drug-trial-for-alcohol-use-disorder

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-medicine-engages-government-and-political-affairs-firm-to-advance-psychedelic-therapeutics-and-regulatory-advocacy

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION